Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

33 results about "Soft tissues tumors" patented technology

Methods and compositions for modulating cell proliferation and cell death

Methods and compositions for modulating the FGF effect on the sensitivity of malignant and normal cells to anticancer agents are provided. In particular, methods and compositions for inhibiting FGF-induced resistance to a broad spectrum of anticancer agents in solid and soft-tissue tumors, metastatic lesions, leukemia and lymphoma are provided. Preferably, the compositions include at least one FGF inhibitor in combination with a cytotoxic agents, e.g., antimicrotubule agents, topoisomerase I inhibitors, topoisomerase II inhibitors, antimetabolites, mitotic inhibitors, alkylating agents, intercalating agents, agents capable of interfering with a signal transduction pathway (e.g., g., a protein kinase C inhibitor, e.g., an anti-hormone, e.g., an antibody against growth factor receptors), an agent that promotes apoptosis and / or necrosis, and interferon, an interleukin, a tumor necrosis factor, and radiation. In other embodiments, methods and composition for protecting a cell in a subject, from one or more of killing, inhibition of growth or division or other damage caused, e.g., by a cytotoxic agent, are provided. Preferably, the method includes: administering, to the subject, an effective amount of at least one FGF agonist, thereby treating the cell, e.g., protecting or reducing the damage to the dividing cell from said cytotoxic agent.
Owner:AU JESSIE L S +1

Radio-frequency electrical membrane breakdown for the treatment of high risk and recurrent prostate cancer, unresectable pancreatic cancer, tumors of the breast, melanoma or other skin malignancies, sarcoma, soft tissue tumors, ductal carcinoma, neoplasia, and intra and extra luminal abnormal tissue

An imaging, guidance, planning and treatment system integrated into a single unit or assembly of components, and a method for using same, that can be safely and effectively deployed to treat prostate cancer in all medical settings, including in a physician's office or in an outpatient setting. The system utilizes the novel process of Radio-Frequency Electrical Membrane Breakdown (“EMB” or “RFEMB”) to destroy the cellular membranes of unwanted or cancerous tissue without denaturing the intra-cellular contents of the cells comprising the tissue, thereby exposing tumor antigens and other intra-cellular components which can have an immunologic effect on local or distant cancerous tissue, with or without the addition of immunologic adjutant drugs. The system preferably comprises at least one EMB treatment probe 20, at least one trackable biopsy needle 200, at least one trackable anesthesia needle 300, and at least one controller unit for at least partially automating the treatment process.
Owner:IMMUNSYS INC

Compositions and methods for treatment of tumors by direct administration of a radioisotope

This invention provides a safer and more effective treatment for non-intracavitary undesirable tissue masses, especially bone cancer and soft tissue tumors. The method involves the direct administration of a therapeutically-effective dose of a formulated radioisotope composition nearby or directly into the tissue mass. Small volumes of the composition are used.Administration of the dose for bone cancer may be done through a hole or multiple holes created in the bone using a miniature drill. Delivery of the dose directly into a tumor may be accomplished using a microsyringe or a miniature pump capable of accurately delivering microliter amounts of material.
Owner:ISOTHERAPEUTICS GROUP +1

Mphosph1 peptides and vaccines including the same

As discussed in greater detail herein, isolated epitope peptides derived from MPHOSPH1 bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL) and thus are suitable for use in the context of cancer immunotherapy, more particularly cancer vaccines. The inventive peptides encompass both the above-mentioned MPHOSPH1-derived amino acid sequences and modified versions thereof, in which one, two, or several amino acids are substituted, deleted, inserted or added, provided such modified versions retain the requisite CTL inducibility of the original sequences. Further provided are polynucleotides encoding any of the aforementioned peptides as well as pharmaceutical agents or compositions that include any of the aforementioned peptides or polynucleotides. The peptides, polynucleotides, and pharmaceutical agents or compositions of this invention find particular utility in either or both of the treatment and prevention of cancers and tumors, including, for example, bladder cancer, breast cancer, cervical cancer, cholangiocellular carcinoma, CML, colorectal cancer, gastric cancer, NSCLC, lymphoma, osteosarcoma, prostate cancer, renal cancer and soft tissue tumor.
Owner:ONCOTHERAPY SCI INC

Application of GPS2 gene in preparation of drugs for prognosis, diagnosis or prevention and treatment of soft tissue tumor

The invention belongs to the field of biological medicines and relates to an application of a GPS2 gene in preparation of drugs for prognosis, diagnosis or prevention and treatment of soft tissue tumor. The GPS2 gene is in low expression in soft-tissue sarcoma such as liposarcoma, and proliferation of the liposarcoma can be promoted by inhibiting the expression of the GPS2 gene. The expression of the GPS2 gene has obvious relevance with prognosis of the liposarcoma, which shows that the GPS2 gene can be used for clinical pathological diagnosis of patients with liposarcoma. The GPS2 gene can be used as a tumor-suppressing gene in the liposarcoma, and can be used as a possible prognostic marker and a therapeutic molecule of the liposarcoma.
Owner:INST OF RADIATION MEDICINE ACAD OF MILITARY MEDICAL SCI OF THE PLA

Hjurp peptides and vaccines including the same

Isolated peptides derived from SEQ ID NO: 50 and fragments thereof that bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL) and thus are suitable for use in the context of cancer immunotherapy, more particularly cancer vaccines are described herein. The inventive peptides encompasses both the above mentioned amino acid sequences and modified versions thereof, in which one, two, or several amino acids sequences substituted, deleted, added or inserted, provided such modified versions retain the requisite cytotoxic T cell inducibility of the original sequence. Further provided are nucleic acids encoding any of the aforementioned peptides as well as pharmaceutical agents, substances and / or compositions that include or incorporate any of the aforementioned peptides or nucleic acids. The peptides, nucleic acids, pharmaceutical agents, substances and compositions of this invention find particular utility in the treatment of cancers and tumors, including, for example, AML, bladder cancer, breast cancer, cervical cancer, cholangiocellular carcinoma, CML, colorectal cancer, esophagus cancer, Diffused-type gastric cancer, liver cancer, NSCLC, lymphoma, osteosarcoma, ovarian cancer, pancreatic cancer, prostate cancer, renal carcinoma, SCLC, soft tissue tumor and testicular tumor.
Owner:ONCOTHERAPY SCI INC

Whole-course supervision system and method for soft tissue tumor informatization pathology auxiliary diagnosis

The invention belongs to the field of tumor information processing, and provides a whole-course supervision system and method for soft tissue tumor informatization pathology auxiliary diagnosis. The system comprises: a clinical data management platform in which clinical data of soft tissue tumors and expression profiles or / and characteristic spectra of different types of soft tissue tumors at different levels are pre-stored; a pathological diagnosis data platform which is used for receiving clinical data, pathological histological images, immunohistochemical results and molecular genetics results of patients to form expression profiles or / and characteristic spectra of different levels, comparing the expression profiles or / and characteristic spectra with the expression profiles or / and characteristic spectra of corresponding levels in the clinical data management platform, determining the same tumor type determined at different levels as a final pathological diagnosis type, and generating a standardized diagnosis report; and a prognosis data information platform which is used for evaluating prognosis risk factors and feeding back the prognosis risk factors to the pathological diagnosis data platform, establishing a clinical prediction model, evaluating the survival rate, regularly prompting follow-up visit patient time and content, and recording follow-up visit information.
Owner:SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG FIRST MEDICAL UNIVERSITY

Immunotoxin derived from a recombinant human autoantibody and method of using thereof

The invention is directed to an immunotoxin directed at fetal AchR, wherein the immunotoxin may comprises a human Fab fragment based on a human autoantibody or human combinatorial CDNA library and may be a pseudomonas exotoxin A-based single chain Fv IT (35-scFV-ETA). The invention is further directed to method of treating a patient with soft tissue tumor comprising the step of exposing the patient to the immunotoxin of the invention.
Owner:ISIS INNOVATION LTD

Cdca5 peptides and vaccines including the same

Isolated peptides derived from SEQ ID NO: 21 and fragments thereof that bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL) and thus are suitable for use in the context of cancer immunotherapy, more particularly cancer vaccines, are described herein. The inventive peptides encompass both the above mentioned amino acid sequences and modified versions thereof, in which one, two, or several amino acids are substituted, deleted, inserted or added, provided such modified versions retain the requisite HLA binding and / or CTL inducibility of the original sequences. Further provided are nucleic acids encoding any of the aforementioned peptides as well as pharmaceutical agents, substances and / or compositions that include or incorporate any of the aforementioned peptides or nucleic acids. The peptides, nucleic acids, pharmaceutical agents, substances and compositions of this invention find particular utility in the treatment of cancers and tumors, including, for example, AML, bladder cancer, breast cancer, cervical cancer, cholangiocellular carcinoma, CML, colorectal cancer, esophagus cancer, gastric cancer, gastric diffuse-type cancer, lung cancer, lymphoma, prostate cancer, SCLC and soft tissue tumor.
Owner:ONCOTHERAPY SCI INC

Radio-frequency electrical membrane breakdown for the treatment of high risk and recurrent prostate cancer, unresectable pancreatic cancer, tumors of the breast, melanoma or other skin malignancies, sarcoma, soft tissue tumors, ductal carcinoma, neoplasia, and intra and extra luminal abnormal tissue

An imaging, guidance, planning and treatment system integrated into a single unit or assembly of components, and a method for using same, that can be safely and effectively deployed to treat prostate cancer in all medical settings, including in a physician's office or in an outpatient setting. The system utilizes the novel process of Radio-Frequency Electrical Membrane Breakdown (“EMB” or “RFEMB”) to destroy the cellular membranes of unwanted or cancerous tissue without denaturing the intra-cellular contents of the cells comprising the tissue, thereby exposing tumor antigens and other intra-cellular components which can have an immunologic effect on local or distant cancerous tissue, with or without the addition of immunologic adjutant drugs. The system preferably comprises at least one EMB treatment probe 20, at least one trackable biopsy needle 200, at least one trackable anesthesia needle 300, and at least one controller unit for at least partially automating the treatment process.
Owner:IMMUNSYS INC

Methods and compositions for modulating cell proliferation and cell death

Methods and compositions for modulating the FGF effect on the sensitivity of malignant and normal cells to anticancer agents are provided. In particular, methods and compositions for inhibiting FGF-induced resistance to a broad spectrum of anticancer agents in solid and soft-tissue tumors, metastatic lesions, leukemia and lymphoma are provided. Preferably, the compositions include at least one FGF inhibitor in combination with a cytotoxic agents, e.g., antimicrotubule agents, topoisomerase I inhibitors, topoisomerase II inhibitors, antimetabolites, mitotic inhibitors, alkylating agents, intercalating agents, agents capable of interfering with a signal transduction pathway (e.g., g., a protein kinase C inhibitor, e.g., an anti-hormone, e.g., an antibody against growth factor receptors), an agent that promotes apoptosis and / or necrosis, an interferon, an interleukin, a tumor necrosis factor, and radiation.In other embodiments, methods and composition for protecting a cell in a subject, from one or more of killing, inhibition of growth or division or other damage caused, e.g., by a cytotoxic agent, are provided. Preferably, the method includes: administering, to the subject, an effective amount of at least one FGF agonist, thereby treating the cell, e.g., protecting or reducing the damage to the dividing cell from said cytotoxic agent.
Owner:AU JESSIE L S +1

Piston type bone and soft tissue tumor biopsy needle

The invention provides a piston type bone and soft tissue tumor biopsy needle. The piston type bone and soft tissue tumor biopsy needle comprises a needle kernel (1), a thin-wall needle tube (3) and a silicone rubber sealing piece (2). The needle kernel (1) is composed of a handle cover (1-1) and a needle core (1-2) fixedly connected with the handle cover (1-1), the thin-wall needle tube (3) is composed of a handle body (3-1) and a tube sleeve (3-2), wherein the handle body and the tube sleeve are integrated, the needle core (1-2) is also a piston rod, and when the needle core (1-2) moves backwards through the sealing effect of the silicon rubber sealing piece (2), negative pressure is formed on the front section of the tube sleeve (3-2).
Owner:周晓光

Methods for Treatment of Tumors by Direct Administration of a Radioisotope

This invention provides a safer and more effective treatment for non-intracavitary undesirable tissue masses, especially bone cancer and soft tissue tumors. The method involves the direct administration of a therapeutically-effective dose of a formulated radioisotope composition nearby or directly into the tissue mass. Small volumes of the composition are used.Administration of the dose for bone cancer may be done through a hole or multiple holes created in the bone using a miniature drill. Delivery of the dose directly into a tumor may be accomplished using a microsyringe or a miniature pump capable of accurately delivering microliter amounts of material.
Owner:GABRIEL INST +1

Medical formula food for soft tissue tumor

The invention belongs to the technical field of formulae of homology of medicine and food and new resource foods, and in particular provides a medical formula food, a specific medical formula food or a non-specific medical formula food for patients with soft tissue tumors. The formula food is processed by following the requirements of general rule of formula food for special medical purpose, combining the physical constitution of the patients with soft tissue tumors, reasonably matching a plurality of traditional Chinese medicines of homology of medicine and food according to the essence theory of traditional Chinese medicine, and mixing a plurality of edible and medical traditional Chinese medicine extract essence extracted by prehydrolysis SBE technology, a plurality of microcapsuled probiotics and biological enzymolysis extracted short peptides, prebiotics, amino acids, carbohydrates, as well as health-care grease, a plurality of vitamins and mineral substances. The medical formula food provided in the invention can meet the nutritive requirement of the patients with soft tissue tumor as a single nutritive source, and has the efficacy of clearing away heat and toxic materials, eliminating swelling, removing stasis, promoting blood circulation to remove blood stasis, resolving hard lump, benefiting qi and nourishing blood and enhancing immunity.
Owner:JINSHANMEI BIOTECH

Preparation method and application of tissue repair promoting hydrogel with antitumor and antibacterial functions

The invention belongs to the field of biomedical materials, and concretely relates to a preparation method and application of a tissue repair promoting hydrogel with antitumor and antibacterial functions. The preparation method of the hydrogel for promoting tissue repair mainly comprises the following steps: firstly, modifying chitosan with arginine, then physically compounding the modified chitosan with polydopamine and nano-hydroxyapatite to form an arginine modified chitosan-polydopamine / nano-hydroxyapatite solution, and finally, crosslinking the solution with a hydrophilic molecule (OHC-PEG-CHO) with aldehyde groups at two ends to form the hydrogel. The tissue repair promoting hydrogel constructed by the invention has a three-dimensional network structure, can inhibit the growth of tumor cells and bacteria, but does not obviously inhibit the growth of normal cells. When the hydrogel is used for defect filling or skin wound repair after skin or soft tissue tumor excision, the effects of efficiently inhibiting bacteria, promoting tissue repair, preventing scar tissue formation and inhibiting local tumor recurrence can be achieved, and the hydrogel has a good clinical applicationprospect.
Owner:SICHUAN UNIV

Culture medium for culturing primary cells of solid tumors of bone and soft tissue tumors

The invention discloses a culture medium for culturing primary cells of solid tumors of bone and soft tissue tumors. The culture medium for culturing the primary cells of the solid tumors of the bone and soft tissue tumors provided by the invention is a special serum-free culture medium, and the culture medium is used for carrying out in-vitro suspension culture on solid tumor cells derived from the bone and soft tissue tumors, so that the interference of normal cells can be eliminated to the greatest extent while normal amplification of the tumor cells can be ensured. The bone and soft tissue tumor solid tumor primary cell culture obtained by the method can be used for various cellular in-vitro experiments, next-generation sequencing, animal model construction, cell line construction and the like. Predictably, the culture method has a wide application prospect in the fields of research and clinical diagnosis and treatment of solid tumors of bone and soft tissue tumors.
Owner:SUZHOU GENOARRAY

MPHOSPH1 peptides and vaccines including the same

ActiveUS9458447B2Induce potent and specific immune responsesPeptide/protein ingredientsHydrolasesNucleotideProstate cancer
As discussed in greater detail herein, isolated epitope peptides derived from MPHOSPH1 bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL) and thus are suitable for use in the context of cancer immunotherapy, more particularly cancer vaccines. The inventive peptides encompass both the above-mentioned MPHOSPH1-derived amino acid sequences and modified versions thereof, in which one, two, or several amino acids are substituted, deleted, inserted or added, provided such modified versions retain the requisite CTL inducibility of the original sequences. Further provided are polynucleotides encoding any of the aforementioned peptides as well as pharmaceutical agents or compositions that include any of the aforementioned peptides or polynucleotides. The peptides, polynucleotides, and pharmaceutical agents or compositions of this invention find particular utility in either or both of the treatment and prevention of cancers and tumors, including, for example, bladder cancer, breast cancer, cervical cancer, cholangiocellular carcinoma, CML, colorectal cancer, gastric cancer, NSCLC, lymphoma, osteosarcoma, prostate cancer, renal cancer and soft tissue tumor.
Owner:ONCOTHERAPY SCI INC

Double sustained release biological agent for tumor local ablation therapy

InactiveCN101450035BPermanent disruption of blood supplyDisrupted blood supplyOrganic active ingredientsPeptide/protein ingredientsCobra venomSpleen
The invention discloses a dual slow release biological preparation for tumor local ablation therapy, which comprises temperature sensing type gel, ricin, noradrenalin and poison microsphere carried with cobra venom cell and is made by the temperature sensing type gel packaging the noradrenalin, the ricin and the poison microsphere carried with cobra venom cell. The concentration of the temperature sensing type gel is 15-45, the temperature sensing type gel with concentration of 15-4501AF3450er ml contains the noradrenalin 10-100 mu g, the ricin 0. 1-1 mu g, the poison microsphere carried withcobra venom cell 2-20 mu g. The invention can be injected into the a nude mice tumor tissue of human hepatocellular carcinoma or can be injected with rabbit home position liver tumor VX2 under ultrasonic guiding in experiment, the invention has obvious anti-tumor effect, can be applied for local ablation therapy of human liver, kidney, pancreas, spleen, prostate gland, uterus, ovary, retroperitoneal and superficial soft tissue tumors under ultrasonic wave or CT guiding.
Owner:FUJIAN MEDICAL UNIV UNION HOSPITAL

Tumor tissue specimen automatic selecting device in bone and soft tissue tumor needle biopsy

The invention belongs to the technical field of medical instruments, and discloses an automatic tumor tissue specimen selecting device in a bone and soft tissue tumor needle biopsy operation, a metal cup for containing specimens is placed in a semitransparent liquid storage tank, a vertical clamping groove is formed in the metal cup, and a cross-shaped crossed blade is fixed to the metal cup through the vertical clamping groove; a hexagonal prism is fixed to the middle of the cross-shaped crossed blade and connected with a transparent circular cover plate, and a manual rotating shaft is fixed to the transparent circular cover plate. The semitransparent liquid storage tank is provided with an inlet hole and an outlet hole, the inlet hole and the outlet hole are provided with switches, a circular opening is formed right above the semitransparent liquid storage tank, and the position of the inlet hole in the semitransparent liquid storage tank is higher than that of the outlet hole. According to the invention, tumor tissue specimens required in a needle biopsy operation can be quickly separated from other unwanted tissues and blood clots, so that useful tumor tissue specimens can be conveniently and quickly selected, and the burden of a surgeon is relieved; the operation time is shortened, and the operation cost of a patient is reduced.
Owner:XIANGYA HOSPITAL CENT SOUTH UNIV

Four-limb soft tissue tumor puncture sampling device

InactiveCN113647998AFacilitate direct researchEasy to grab and fixSurgical needlesVaccination/ovulation diagnosticsSoft tissues tumorsBiomedical engineering
The invention discloses a four-limb soft tissue tumor puncture sampling device which comprises a puncture tube, one end of the puncture tube is detachably connected with a needle drawing cylinder, the needle drawing cylinder is internally communicated with the puncture tube, the puncture tube is connected with a plurality of push rods in an inserted mode, the push rods are distributed around the axis of the puncture tube at intervals, and the ends, away from the needle drawing cylinder, of the push rods are hinged to cutting pieces. A turnover driving part is arranged on the peripheral surface, far away from the tail end of the needle drawing cylinder, of the puncture tube, and the driving end of the turnover driving part directly faces the cutting part; when the hinge points between the cutting pieces and the push rod are pushed by the push rod to directly face the driving end of the turnover driving piece, the cutting pieces are all turned over in the axis direction of the puncture tube relative to the hinge points of the cutting pieces. The device has the function of taking out tumor block samples and liquid samples in a puncture mode. Compared with the prior art, the function of taking out the blocky tumor is added, the taken-out tumor blocky sample can be directly researched conveniently, and the effects of improving the research judgment accuracy and increasing the research speed are achieved.
Owner:HUNAN PROVINCIAL TUMOR HOSPITAL

Application of cox‑2 in preparation of diagnostic reagents for diagnosis and detection of canine tumors

InactiveCN104678099BMaterial analysisTesticular stromal tumorPeroxidase
The invention discloses an application of COX-2 (cyclo-oxygen-ase-2) in preparation of a diagnostic reagent for dog tumor diagnosis and detection. The experiment research shows that the positive expression rate of COX-2 in dog tumors such as a breast tumor, skin and soft-tissue tumors, a perianal tumor, a testicular tumor and vagina and uterine tumors is 76.1%, the positive expression rate of COX-2 in normal tissue is only 20%, so that COX-2 can be applied as a dog tumor marker, the expression condition of COX-2 is detected with an immunohistochemical method, and a result can be taken as one of evidence items for clinically diagnosing whether a person suffers from the dog tumor. The invention further discloses a kit for detecting COX-2 and a detection method. The kit contains a 3% H2O2 solution, a citrate buffer solution, a PBS (poly butylenes succinate) buffer solution, a mouse COX-2 monoclonal antibody, a goat anti-mouse IgG antibody, a DAB (diaminobenzidine) developing solution and distilled water. The detection method comprises the step of streptaridin-peroxidase dyeing.
Owner:NANJING AGRICULTURAL UNIVERSITY +1

Method for culturing primary cells of solid tumors of bone and soft tissue tumors

The invention discloses a method for culturing primary cells of solid tumors of bone and soft tissue tumors. The invention provides a method for culturing primary cells of solid tumors of bone and soft tissue tumors and a matched reagent. According to the technical core, a mild cell dissociation reagent is used for treating bone and soft tissue tumor solid tumor tissues, so that the activity of tumor cells in the tissues is ensured to the greatest extent; and a special serum-free culture medium is prepared, solid tumor cells from bone and soft tissue tumors are subjected to in-vitro culture by using a suspension culture system, and interference of normal cells is eliminated to the greatest extent while normal amplification of the tumor cells is ensured. The bone and soft tissue tumor solid tumor primary cell culture obtained by the method can be used for various cellular in-vitro experiments, next-generation sequencing, animal model construction, cell line construction and the like. Predictably, the culture method has a wide application prospect in the fields of research and clinical diagnosis and treatment of solid tumors of bone and soft tissue tumors.
Owner:SUZHOU GENOARRAY

Tumor cell vaccine targeting CAFs, and preparation method and application thereof

The invention discloses a preparation method of a tumor cell vaccine targeting CAFs, and belongs to the technical field of biological medicines, the method is as follows: lentiviral packaging plasmids are adopted to infect tumor cells to obtain a stable expression strain, and then the stable expression strain is inactivated to obtain the tumor cell vaccine targeting CAFs; the invention also discloses application of the vaccine prepared by the method. On the basis of a brand-new preparation method, the prepared vaccine can more stably express an antigen, the immunotherapy response rate is higher, the effect is better and more stable, and the obtained vaccine is a broad-spectrum vaccine and can treat more than 90% of tumors from epithelium, part of soft tissue tumors and melanoma; besides, the vaccine can also enhance the radiosensitivity of tumors, can achieve a better effect when used in combination with radiotherapy, especially ablation radiotherapy, and can improve fibrosis caused by radiotherapy and reduce toxic and side effects of radiotherapy.
Owner:SICHUAN CANCER HOSPITAL

Double sustained release biological agent for tumor local ablation therapy

InactiveCN101450035APermanent disruption of blood supplyDisrupted blood supplyOrganic active ingredientsPeptide/protein ingredientsCobra venomSpleen
The invention discloses a dual slow release biological preparation for tumor local ablation therapy, which comprises temperature sensing type gel, ricin, noradrenalin and poison microsphere carried with cobra venom cell and is made by the temperature sensing type gel packaging the noradrenalin, the ricin and the poison microsphere carried with cobra venom cell. The concentration of the temperature sensing type gel is 15-45, the temperature sensing type gel with concentration of 15-4501AF3450er ml contains the noradrenalin 10-100 mu g, the ricin 0. 1-1 mu g, the poison microsphere carried with cobra venom cell 2-20 mu g. The invention can be injected into the a nude mice tumor tissue of human hepatocellular carcinoma or can be injected with rabbit home position liver tumor VX2 under ultrasonic guiding in experiment, the invention has obvious anti-tumor effect, can be applied for local ablation therapy of human liver, kidney, pancreas, spleen, prostate gland, uterus, ovary, retroperitoneal and superficial soft tissue tumors under ultrasonic wave or CT guiding.
Owner:FUJIAN MEDICAL UNIV UNION HOSPITAL

Design kit for targeted detection of small round cell tumor fusion gene panel of soft tissue tumor

The invention belongs to the technical field of gene sequencing, and discloses a next-generation sequencing kit for targeted detection of formalin-immobilized paraffin embedded (FFPE) soft tissue small round cell tumor fusion genes. The kit comprises a DNA extraction reagent for DNA extraction; an RNA extraction and transcription reagent is used for cDNA acquisition; a multiplex PCR primer and a multiplex PCR amplification reagent of the 30 gene are used for specific amplification of the 30 gene; dNA purification magnetic beads are used for purifying the product; a library building reagent is used for building a DNA / cDNA library for next-generation sequencing. The 30 gene multiple PCR primers are synthesized, then primers are synthesized in related biological companies, multiple PCR is completed under the condition that mismatching of DNA melting temperature is reduced to the maximum extent, and detection of amplification of target fusion genes is completed; the reagents used in the invention can be prepared through purchased commercial reagents or can be directly purchased. The invention can provide direct genetic basis for diagnosis and differential diagnosis of various tumors in soft tissue small round cell tumors.
Owner:WEST CHINA HOSPITAL SICHUAN UNIV

Soft tissue tumor specimen incision fixator and preparation method of sucker thereof

The invention discloses a soft tissue tumor specimen incision fixator and a preparation method of a sucker thereof. The soft tissue tumor specimen incision fixator comprises a storage box, wherein anopening is formed in one end of the storage box, a grid tray with the adjustable height is arranged in the storage box, a groove is formed in the inner wall of the storage box, a connecting rod is vertically arranged in the groove, a connector is arranged at the position, which is located in the groove, of the grid tray, a round hole is formed in the middle of the connector, the surface of the connecting rod is sleeved with the connector through the round hole, and a fastening ring is arranged at the joint of the connector and the connecting rod; and a stand column is arranged on the upper surface of the storage box, an adjusting rod rotationally connected with the stand column is arranged on the surface of the stand column, and a sucker is arranged at one end of the adjusting rod. The preparation method of the sucker comprises the steps of mixing, kneading, open milling, primary vulcanization and secondary vulcanization. The soft tissue tumor specimen incision fixator is provided withthe liftable grid tray, and the sucker can be adjusted under the action of the adjusting rod, so that the fixator can be suitable for soft tissue tumor specimens with different sizes and is convenient to use.
Owner:XIEHE HOSPITAL ATTACHED TO TONGJI MEDICAL COLLEGE HUAZHONG SCI & TECH UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products